Sort   by:  
 Page size 
GenomicsCycling cancer persisters arise from lineages with distinct transcriptional and metabolic programs
Cycling cancer persisters arise from lineages with distinct transcriptional and metabolic programs
PRJNA634136 | ENA
TranscriptomicsCycling cancer persisters arise from lineages with distinct transcriptional and metabolic programs
Non-genetic mechanisms have recently emerged as important drivers of therapy failure in cancer, where some cancer cells can enter a reversible drug-tolerant persister state in response to treatment. While most cancer persisters, like their bacterial counterparts, remain arrested in the presence of d...
ORGANISM(S): Homo sapiens 
2020-05-21 | GSE150949 | GEO
GenomicsOntogeny and Vulnerability of Lapatinib Drug-Tolerant Persisters in HER2-positive Breast Cancer
Ontogeny and Vulnerability of Lapatinib Drug-Tolerant Persisters in HER2-positive Breast Cancer
PRJNA657182 | ENA
UnknownOntogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.
Not available
S-EPMC8983469 | biostudies-literature
GenomicsThe Ontogeny and Vulnerabilities of Lapatinib Drug Tolerant Persisters [NPY1R]
The Ontogeny and Vulnerabilities of Lapatinib Drug Tolerant Persisters [NPY1R]
PRJNA648987 | ENA
UnknownElevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells.
Not available
S-EPMC9978888 | biostudies-literature
UnknownFXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters.
Not available
S-EPMC10645391 | biostudies-literature
TranscriptomicsOntogeny and Vulnerability of Lapatinib Drug-Tolerant Persisters in HER2-positive Breast Cancer
Despite advances in HER2-targeted therapeutics, resistance remains a significant clinical problem in HER2-positive (HER2+) breast cancer, especially in the metastatic setting. Drug-tolerant persisters (DTPs), a sub-population of cancer cells that survive via reversible, non-genetic mechanisms, are i...
ORGANISM(S): Homo sapiens 
2021-12-13 | GSE156246 | GEO
GenomicsDrug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms
Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms
PRJNA1331798 | ENA
UnknownGlucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
Not available
S-EPMC5497794 | biostudies-literature
Sort   by:  
 Page size